For the quarter ending 2026-03-31, ANAB made $25,556K in revenue. -$53,006K in net income. Net profit margin of -207.41%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 25,556 | 108,249 | 76,320 | 22,263 |
| research and development | 33,991 | 25,559 | 31,407 | 37,824 |
| General and administrative | 26,202 | 15,789 | 10,209 | 10,609 |
| Acquired in-process research and development | - | 0 | - | - |
| Total operating expenses | 60,193 | 41,348 | 41,616 | 48,433 |
| Loss from operations | -34,637 | 66,901 | 34,704 | -26,170 |
| Interest income | 2,653 | 2,508 | 2,924 | 3,654 |
| Non-cash interest expense for the sale of future royalties | 20,859 | 19,711 | 22,515 | 19,606 |
| Other (expense) income, net | -1 | -3 | 0 | 3,531 |
| Total other expense, net | -18,207 | -17,206 | -19,591 | -12,421 |
| Gain before income taxes | -52,844 | 49,695 | 15,113 | -38,591 |
| Provision for income taxes | 40 | 81 | 0 | 39 |
| Net gain | -52,884 | 49,614 | 15,113 | -38,630 |
| Unrealized loss on available for sale securities | -122 | -71 | 53 | -167 |
| Comprehensive gain | -53,006 | 49,543 | 15,166 | -38,797 |
| Basic EPS | -1.84 | 1.786 | 0.54 | -1.34 |
| Diluted EPS | -1.84 | 1.865 | 0.52 | -1.34 |
| Basic Average Shares | 28,691,000 | 27,745,000 | 27,833,000 | 28,810,000 |
| Diluted Average Shares | 28,691,000 | 26,560,000 | 29,018,000 | 28,810,000 |
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)